论文部分内容阅读
目的探讨多西紫杉醇(TXT)联合卡铂(CBP)治疗非小细胞肺癌(NSCLC)的剂量限制性毒性(DLT)和最大耐受剂量(MTD)。方法TXT按剂量递增分为65 mg／m2、75 mg／m2、85 mg／m2,第1天,静脉滴注,剂量递增至出现DLT;CBP以AUC定义为5计算剂量,第1天,静脉滴注,3周重复。结果16例NSCLC患者共完成54个周期化疗,中位周期数4个。15例患者可评价疗效,CR 1例,PR 7例,SD 3例,PD 4例。DLT为中性粒细胞减少,TXT的MTD为85 mg/m2。结论我们推荐TXT 75 mg／m2,CBP以AUC定义为5计算剂量,均为第1天使用,3周重复的方案作为初治NSCLC的化疗方案。
Objective To investigate the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of docetaxel (TXT) combined with carboplatin (CBP) in the treatment of non-small cell lung cancer (NSCLC). Methods TXT was divided into 65 mg / m 2, 75 mg / m 2 and 85 mg / m 2 in dose increments. On the first day, TXT increased dose to DLT. CBP was defined as AUC of 5 as calculated dose. On day 1, Instillation, repeated 3 weeks. Results A total of 54 cycles of chemotherapy were performed in 16 NSCLC patients with 4 median cycles. Fifteen patients were evaluated for efficacy, CR 1, PR 7, SD 3, and PD 4. DLT is neutropenia, TXT has a MTD of 85 mg / m2. Conclusions We recommend TXT 75 mg / m2 and CBP with AUC defined as a calculated dose of 5, both for the first day of use and for a three-week regimen as a regimen for naive NSCLC.